Benefit assessment in Germany

New England Journal of Medicine

Volumn 362, Issue 4, 2010, Pages

  Hasford, Joerg ^a   Lehmacher, Walter ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTERY DISEASE; CLINICAL TRIAL; GERMANY; HEALTH CARE; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; NEOPLASM; POLITICS; PRIORITY JOURNAL;

ASPIRIN; CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS RESEARCH; GERMANY; GOVERNMENT AGENCIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NATIONAL HEALTH PROGRAMS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 75449083951     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Sawicki PT. Communal responsibility for health care - the example of benefit assessment in Germany. N Engl J Med 2009;61(20):e42.
2. Hasford J, Bramlage P, Koch G, et al. Inconsistent trial assessments by the NICE and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. J Clin Epidemiol (in press).
3. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-3.
4. Antes G, Jöckel KH, Kohlmann T, Raspe H, Wasem J. Commented synopsis on the cost-benefit analysis of drugs. (In German.) (Accessed January 11, 2010, at http://www.bmg.bund.de/cln-151/nn-1168258/SharedDocs/Downloads/DE/Neu/ Kurzbericht-16-04-08--Synopse-Kosten-Nutzen-Arzneimittel.html?--nnn=true.)